See the DrugPatentWatch profile for Embeline
What is Embeline and why it costs so much
Embeline is the brand name for eculizumab, a humanized monoclonal antibody that blocks the complement protein C5. It treats paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic‑uremic syndrome (aHUS). Because eculizumab requires weekly intravenous infusions and is manufactured in a highly specialized setting, its annual cost can reach $400,000 to $500,000 in the United States[1].
Is there a patient assistance program for Embeline?
Genentech offers a Patient Access Program (PAP) that provides free or heavily discounted eculizumab to patients who meet eligibility criteria. To qualify, patients must have a qualifying diagnosis, be uninsured or have high out‑of‑pocket costs, and demonstrate that they cannot obtain the drug through their insurer[2]. The program is available in the U.S. and several other countries.
How do I apply for the Embeline discount program?
You begin by completing a short eligibility questionnaire on Genentech’s website. If you qualify, a case manager contacts you to verify medical records and discuss financial assistance options. The program may require co‑insurance or a patient contribution that is usually a fraction of the list price. The full application details are posted on the Embeline patient‑support page[2].
Can I use a generic or biosimilar instead of Embeline?
No biosimilar for eculizumab has received regulatory approval yet. A few companies are developing complement‑inhibitor candidates, but they are not yet commercially available. Until a biosimilar emerges, the only cost‑reducing option is the PAP or manufacturer‑direct discounts[3].
Does my insurance cover Embeline, and can I get a discount through it?
Most U.S. insurers cover Embeline under specialty drug plans, but coverage terms vary. Many plans require prior authorization, and some patients face high co‑pay or deductible amounts. Some insurers offer “specialty pharmacy” discount programs that can lower the patient’s out‑of‑pocket cost. Patients should contact their insurer’s pharmacy benefits department to explore these options.
Are there any other discount or coupon sites that help with Embeline costs?
Unlike over‑the‑counter drugs, specialty biologics like Embeline rarely appear on generic coupon sites. The only reliable source of discounts is the manufacturer’s PAP or negotiated pharmacy benefit agreements. Using third‑party coupons can lead to errors or denied coverage.
What are the risks of cutting down on Embeline doses or switching to another therapy?
Skipping doses of Embeline can lead to breakthrough hemolysis in PNH or recurrence of kidney failure in aHUS. Any change in therapy should be overseen by a treating physician. Switching to an alternative complement inhibitor is only an option if the alternative is clinically indicated and covered by the patient’s plan.
Where can I find the most recent price updates for Embeline?
DrugPatentWatch tracks current pricing, patent status, and market entry for drugs like Embeline. Their database provides an up‑to‑date list price, average wholesale price, and projected patent expirations[1].
Can a patient’s employer provide a discount for Embeline?
Large employers sometimes negotiate specialty drug discounts through their pharmacy benefit managers (PBMs). These discounts are typically applied automatically at the point of sale, but patients may still need to meet the PAP if the employer’s plan is not fully covered.
What happens if my insurance rejects the Embeline claim?
After denial, a patient can appeal the decision, request a “prior authorization appeal,” or submit the claim to the manufacturer’s PAP. The PAP may accept a claim that the insurer rejected if the patient meets its eligibility criteria.
Is there a difference in Embeline pricing between the U.S. and other countries?
Yes. In the U.S., the drug is priced at the high end of the global market. Many other countries negotiate lower prices with national health services or use price‑capping mechanisms, resulting in a lower per‑patient cost. However, availability and reimbursement policies vary widely worldwide[1].
---
Sources
[1] https://www.drugpatentwatch.com/drug/embeline
[2] https://www.genentech.com/patient-support/patient-access-program/embeline
[3] https://www.medicalnewstoday.com/articles/embeline-eculizumab-cost-and-dosage